Eterna Therapeutics Inc (ERNA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.83 (+1.86%), Market cap $0.01B, 52-week low–high $0.15 ~ $7.82.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusett
Financial statements, price targets, institutional (13F) holdings and related news for Eterna Therapeutics Inc are updated in real time on BlackAll Trade.
Eterna Therapeutics Inc trades at $3.83 (+1.86%). Real-time quotes and charts are available on BlackAll Trade.
Eterna Therapeutics Inc has a market cap of about $0.01B.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's l